正式启动！第六批高值医用耗材“国采”

Core Viewpoint - The official announcement of the sixth batch of high-value medical consumables centralized procurement marks the start of a new phase in the procurement process, focusing on structured competition and stable supply rather than merely price reduction [2][18]. Procurement Scope and Demand Scale - The procurement covers two main categories: drug-coated balloons and urological interventional consumables. The drug-coated balloons are further divided into coronary and peripheral categories, with specific applications detailed for each [6][11]. - The annual demand structure for drug-coated balloons includes: - Coronary drug-coated balloons: 614,778 units - Peripheral arteriovenous fistula drug-coated balloons: 6,884 units - Peripheral upper knee drug-coated balloons: 61,434 units - Peripheral lower knee drug-coated balloons: 7,002 units [10][11]. Grouping Mechanism - The bidding organization will continue to use a unit-based bidding approach, with A/B group logic based on actual demand structure rather than the number of companies. Group A will cater to mainstream clinical needs, while Group B will follow [12][20]. Proposed Selection Rules - Three differentiated proposed selection rules are established for products based on their competitive status, clearly defining price formation and re-bidding space [13][14]. - For products that are selected, they must meet three conditions, establishing a price constraint to avoid price distortion [14][21]. Secondary Bidding Rules - For products that are included but not selected, a secondary bidding opportunity is allowed under specific conditions, maintaining a ceiling on price increases to prevent strategic high pricing [15][21]. - For products not included, stricter conditions apply for re-bidding, indicating a higher difficulty level for selection compared to included products [16][21]. Policy Signals - The procurement process is shifting from a focus on price suppression to a more refined competitive structure, emphasizing sustainable pricing and allowing smaller companies to participate while maintaining overall price discipline [17][18]. Conclusion - The release of the procurement document indicates a transition to a more structured and refined competitive bidding process for high-value medical consumables, where the focus shifts from price advantages to comprehensive evaluations of cost control, product structure, and supply stability [18][19].